Concepedia

Paul Klekotka

PK

Statistics

Publications

44

Citations

7.3K

H-Index

30

Active since

1993

Affiliations

Amgen (United States)(Current)

Eli Lilly (United States)

University of North Carolina at Chapel Hill

University of California San Diego

Harvard University

Paul Klekotka is an author at Amgen (United States) specializing in pharmacotherapy, medicine, and immunotherapy.

Publications per year

1993–2024

44

Publications

44

SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19

Peter Chen, Ajay Nirula, Barry N. Heller et al. · New England Journal of Medicine · 2020 · 1.4K citations · Full text

, , +14

Effect of Bamlanivimab as Monotherapy or in Combination With Etesevimab on Viral Load in Patients With Mild to Moderate COVID-19

Robert Gottlieb, Ajay Nirula, Peter Chen et al. · JAMA · 2021 · 947 citations · Full text

, , +15

Phase 3 Studies Comparing Brodalumab with Ustekinumab in Psoriasis

Mark Lebwohl, Bruce Strober, Alan Menter et al. · New England Journal of Medicine · 2015 · 806 citations · Full text

, , +10

Peripheral CD103+ dendritic cells form a unified subset developmentally related to CD8α+ conventional dendritic cells

Brian T. Edelson, Wumesh KC, Richard M. Juang et al. · The Journal of Experimental Medicine · 2010 · 708 citations · Full text

, , +16

A prospective phase III, randomized, double‐blind, placebo‐controlled study of brodalumab in patients with moderate‐to‐severe plaque psoriasis

Kim Papp, Kristian Reich, C. Paul et al. · British Journal of Dermatology · 2016 · 459 citations

, , +13

1–5 of 44